National Cancer Institute; Notice of Meeting, 22893 [05-8779]

Download as PDF Federal Register / Vol. 70, No. 84 / Tuesday, May 3, 2005 / Notices determined by the Freedom of Information officials of DHHS or by a court, data contained in the portions of an application which have been specifically identified by page number, paragraph, etc., by the applicant as containing restricted and/or proprietary information shall not be used or disclosed except for evaluation purposes. Dated: April 26, 2005. Jeffrey Shuren, Assistant Commissioner for Policy. [FR Doc. 05–8819 Filed 5–2–05; 8:45 am] BILLING CODE 4160–01–S LaVerne Stringfield, Director, Office of Federal Advisory Committee Policy. [FR Doc. 05–8780 Filed 5–2–05; 8:45 am] DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health BILLING CODE 4140–01–M Notice of Meeting: Secretary’s Advisory Committee on Genetics, Health, and Society Pursuant to Pub. L. 92–463, notice is hereby given of the seventh meeting of the Secretary’s Advisory Committee on Genetics, Health, and Society (SACGHS), U.S. Public Health Service. The meeting will be held from 8:30 a.m. to 5:30 p.m. on June 15, 2005 and 8:30 a.m. to 5:30 p.m. on June 16, 2005 at the Bethesda North Marriott Hotel, 5701 Marinelli Road, North Bethesda, Maryland. The meeting will be open to the public with attendance limited to space available. The meeting will be Webcast. The topics of the first day are expected to be genetic discrimination, direct-to-consumer marketing of genetic tests, and coverage and reimbursement of genetic tests and services. The Committee aims to finalize a report on coverage and reimbursement of genetic tests and services after considering public comments. The topics for the second day are expected to include large population studies of gene-environment interactions and pharmacogenomics. Time will be provided each day for public comments. Under authority of 42 U.S.C. 217a, Section 222 of the Public Health Service Act, as amended, the Department of Health and Human Services established SACGHS to serve as a public forum for deliberations on the broad range of human health and societal issues raised by the development and use of genetic technologies and, as warranted, to provide advice on these issues. The draft meeting agenda and other information about SACGHS, including information about access to the Webcast, will be available at the VerDate jul<14>2003 15:43 May 02, 2005 Jkt 205001 following Web site: https:// www4.od.nih.gov/oba/sacghs.htm. The Committee would welcome hearing from anyone wishing to provide public comment on any issue related to genetics, health and society. Individuals who would like to provide public comment or who plan to attend the meeting and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the SACGHS Executive Secretary, Ms. Sarah Carr, by telephone at 301–496–9838 or e-mail at sc112c@nih.gov. The SACGHS office is located at 6705 Rockledge Drive, Suite 750, Bethesda, MD 20892. DEPARTMENT OF HEALTH AND HUMAN SERVICES 22893 this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. Information is also available on the Institute’s/Center’s home page: https:// deainfo.nci.nih.gov/advisory/dclg/dclg.htm, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS.) Dated: April 25, 2005. LaVerne Y. Stringfield, Director, Office of Federal Advisory Committee Policy. [FR Doc. 05–8779 Filed 5–2–05; 8:45 am] BILLING CODE 4140–01–M National Institutes of Health DEPARTMENT OF HEALTH AND HUMAN SERVICES National Cancer Institute; Notice of Meeting National Institutes of Health Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the National Cancer Institute Directors Consumer Liaison Group. The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. National Center for Research Resources; Notice of Closed Meeting Name of Committee: National Cancer Institute Director’s Consumer Liaison Group. Date: May 26, 2005. Time: 3 p.m. to 5 p.m. Agenda: Opening remarks; approval of minutes February 28–March 1, 2005 DCLG meeting; NCI Director’s Remarks; reports from NCI Listens and Learns Working Groups: Operations Working Group, Summit Working Group, Promotions Working Group, and Evaluation Working Group; DCLG recommendations on the Progress Review Group Process; public comment; next steps. Place: National Institutes of Health, 6116 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call). Contact Person: Nancy Caliman, Executive Secretary, Office of Liaison Activities, National Institutes of Health, National Cancer Institutes, 6116 Executive Boulevard, Suite 220, MS8324, Bethesda, MD 20892, (301) 496–0307, calimann@mail.nih.gov. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on PO 00000 Frm 00053 Fmt 4703 Sfmt 4703 Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Center for Research Resources Special Emphasis Panel. Date: May 6, 2005. Time: 11:30 a.m. to 12 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, One Democracy Plaza, 6701 Democracy Boulevard, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Barbara J. Nelson, PhD., Scientific Review Administrator, Office of Review, National Center for Research Resources, NIH, 6701 Democracy Blvd, Room 1080, 1 Democracy Plaza, Bethesda, MD 20892, (301) 435–0806. This notice is being published less than 15 days prior to the meeting due to the timing E:\FR\FM\03MYN1.SGM 03MYN1

Agencies

[Federal Register Volume 70, Number 84 (Tuesday, May 3, 2005)]
[Notices]
[Page 22893]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-8779]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Meeting

    Pursuant to section 10(a) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of 
the National Cancer Institute Directors Consumer Liaison Group.
    The meeting will be open to the public, with attendance limited to 
space available. Individuals who plan to attend and need special 
assistance, such as sign language interpretation or other reasonable 
accommodations, should notify the Contact Person listed below in 
advance of the meeting.

    Name of Committee: National Cancer Institute Director's Consumer 
Liaison Group.
    Date: May 26, 2005.
    Time: 3 p.m. to 5 p.m.
    Agenda: Opening remarks; approval of minutes February 28-March 
1, 2005 DCLG meeting; NCI Director's Remarks; reports from NCI 
Listens and Learns Working Groups: Operations Working Group, Summit 
Working Group, Promotions Working Group, and Evaluation Working 
Group; DCLG recommendations on the Progress Review Group Process; 
public comment; next steps.
    Place: National Institutes of Health, 6116 Executive Boulevard, 
Rockville, MD 20852, (Telephone Conference Call).
    Contact Person: Nancy Caliman, Executive Secretary, Office of 
Liaison Activities, National Institutes of Health, National Cancer 
Institutes, 6116 Executive Boulevard, Suite 220, MS8324, Bethesda, 
MD 20892, (301) 496-0307, calimann@mail.nih.gov.
    Any interested person may file written comments with the 
committee by forwarding the statement to the Contact Person listed 
on this notice. The statement should include the name, address, 
telephone number and when applicable, the business or professional 
affiliation of the interested person.
    Information is also available on the Institute's/Center's home 
page: https://deainfo.nci.nih.gov/advisory/dclg/dclg.htm, where an 
agenda and any additional information for the meeting will be posted 
when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention Research; 
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer 
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer 
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer 
Control, National Institutes of Health, HHS.)

    Dated: April 25, 2005.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 05-8779 Filed 5-2-05; 8:45 am]
BILLING CODE 4140-01-M

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.